资讯

Stockhead on MSN7 小时

Neurizon’s ALS drug shows safety and extended survival in open-label extension study

Neurizon Therapeutics has reported positive topline results from an open-label extension study of its lead candidate NUZ-001 ...
ALS News Today15 小时

Healthy volunteer study’s results net clinical trial for ALS therapy

The ALS therapy ATH-1105 entered the brain and spinal cord at dose-proportional levels in healthy volunteers, and had a good ...

Surprising gene activity shields certain nerve cells from ALS damage

By analyzing millions of messenger RNA molecules (mRNA) during the course of ALS, researchers at Stockholm University, in ...
News-Medical.Net on MSN10 小时

Researchers gain better understanding of how nerve cells can be protected against ALS

By analyzing millions of messenger RNA molecules (mRNA) during the course of ALS, researchers at Stockholm University, in ...
HealthDay on MSN1 天

Scientists develop brain implant to turn thoughts into speech

Stanford University scientists have developed a brain implant designed to "hear" and vocalize words a person with severe ...
Fierce Biotech1 天

Neurizon becomes 2nd biotech hit with FDA delay for ALS candidate

Yet another biotech is facing a delay from the FDA as the agency reels from intense staffing cuts. | Yet another biotech is ...

Skin-based biomarkers may offer earlier diagnosis for amyotrophic lateral sclerosis

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that causes the gradual loss of motor neurons in the brain and spinal cord, leading to muscle weakness, paralysis, and ...
The Globe and Mail26 天

Amyotrophic Lateral Sclerosis Pipeline Insight 2025: 75+ Companies ...

• Key Amyotrophic Lateral Sclerosis Pipeline Therapies: ION363, FB418, SRK-015, RNS60, QRL-201, SAR443820, MN-166, VM202, VRG-50635, Zilucoplan, and others.